Abstract:Background Primary sclerosing cholangitis (PSC) is an immune-mediated cholestatic liver disease characterized by bile retention, biliary tree destruction, and progressive fibrosis leading to end stage liver disease and transplantation. There is an unmet need to understand the cellular composition of the PSC liver and how it underlies disease pathogenesis. We generated a comprehensive atlas of the PSC liver in comparison to a primary biliary cholangitis (PBC) and reference healthy liver dataset using multiple multi-omic modalities and functional validation. Methods We employed single-cell (sc) RNA-seq (47,156 cells), single-nucleus (sn) RNA-seq (23,000 nuclei) and spatial transcriptomics (1 sample by 10x Visium and 5 samples with multi-region profiling by Nanostring GeoMx Digital Spatial Profiler) to profile the cellular ecosystem in 10 patients with PSC. Transcriptomic profiles were compared to 24 neurologically deceased donor livers (107,542 cells) and spatial transcriptomics controls, 18,240 cells and 20,202 nuclei from 3 patients with PBC, and publicly available scRNA-seq data from 5 uninjured, 2 NAFLD, 2 ALD, and 1 PBC liver samples. Flow cytometry and intracellular cytokine staining was performed to validate PSC-specific differences in immune cell phenotype and function. Results PSC explants with cirrhosis of the liver parenchyma and prominent periductal fibrosis contained a population of hepatocytes expressing a cholangiocyte-like phenotype. These hepatocytes were surrounded by diverse immune cell populations, including monocyte-like macrophages, liver-resident and circulating natural killer cells. PSC-associated cholangiocytes, hepatic stellate cells, and endothelial cells expressed chemokine and cytokine transcripts typically involved in immune cell recruitment. As well, expanded CD4 + T cells, dendritic cells and neutrophils in the PSC liver expressed the corresponding receptors to these chemokines and cytokines, suggesting potential recruitment. Tissue-resident macrophages, by contrast, were reduced in number and exhibited a dysfunctional and downregulated inflammatory response to LPS and IFN-Ɣ stimulation. Conclusions We present a comprehensive atlas of the PSC liver and demonstrate hyper-activation and exhaustion-like phenotypes of myeloid cells and markers of chronic cytokine expression in late-stage PSC lesions. This atlas has the potential to expand our understanding of the cellular complexity of PSC and to inform novel treatment development. Impact and Implications Primary sclerosing cholangitis (PSC) is a rare liver disease characterized by chronic inflammation and irreparable damage to the bile ducts resulting in liver failure. Due to a limited understanding of the underlying pathogenesis of disease, there remains a paucity of treatment options. We sequenced healthy and diseased livers to compare the activity, interactions, and localization of immune and non-immune cells. This revealed that hepatocytes lining PSC scar regions are transforming into cholangiocytes, whereas immune cells are accumulating within the scars. Of these cells, macrophages, which typically contribute to tissue repair, were enriched in immunoregulatory genes and demonstrated a lack of responsiveness to stimulation. These cells may be involved in maintaining hepatic inflammation and could be targeted in novel therapeutic drug development.

Demonstrating the Beneficial Effect of Low Protein Diet in Primary Sclerosing Cholangitis through a Randomized Clinical Trial and Multi-omics Data Analysis

Current Therapeutics in Primary Sclerosing Cholangitis

Gut Pathobiont-Derived Outer Membrane Vesicles Drive Liver Inflammation and Fibrosis in Primary Sclerosing Cholangitis-Associated Inflammatory Bowel Disease

Circulating cell-free messenger RNA secretome characterization of primary sclerosing cholangitis

Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis

A protective effect of inflammatory bowel disease on the severity of sclerosing cholangitis

Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis

Gut Microbiota in Primary Sclerosing Cholangitis: From Prognostic Role to Therapeutic Implications

Suppression of bile acid synthesis as a tipping point in the disease course of primary sclerosing cholangitis

Minocycline in the Treatment of Patients With Primary Sclerosing Cholangitis: Results of a Pilot Study

[Primary sclerosing cholangitis-Diagnosis and treatment 2024]

Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments

Single-cell and spatial transcriptomics characterisation of the immunological landscape in the healthy and PSC human liver

Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis

Protocol for the development of a core outcome set for clinical trials in primary sclerosing cholangitis

The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data

P327 Profiling serum metabolome and lipidome to differentiate primary sclerosing cholangitis from Inflammatory Bowel Disease and healthy controls

A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis

Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study

Gut microbiome in primary sclerosing cholangitis: A review

Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis